Literature DB >> 18948642

The endocannabinoid system: an osteopathic perspective.

John M McPartland1.   

Abstract

The present review provides an update on endocannabinoid basic science and clinical studies and proposes a new model to describe reciprocal interactions between somatic dysfunction and the endocannabinoid system. The endocannabinoid system consists of cannabinoid receptors, endogenous ligands, and ligand-metabolizing enzymes. The system exemplifies the osteopathic principle that the body possesses self-regulatory mechanisms that are self-healing in nature. Enhancing endocannabinoid activity has broad therapeutic potential, including the treatment of patients with somatic dysfunction, chronic pain, and neurodegenerative diseases as well as inflammatory conditions, bowel dysfunctions, and psychological disorders. Blockade of the endocannabinoid system with drugs such as rimonabant and taranabant may oppose self-healing mechanisms and elicit adverse effects. Osteopathic physicians wield several tools that can augment endocannabinoid activity, including lifestyle modifications, pharmaceutical approaches, and osteopathic manipulative treatment.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18948642     DOI: 10.7556/jaoa.2008.108.10.586

Source DB:  PubMed          Journal:  J Am Osteopath Assoc        ISSN: 0098-6151


  3 in total

1.  Obesity, the endocannabinoid system, and bias arising from pharmaceutical sponsorship.

Authors:  John M McPartland
Journal:  PLoS One       Date:  2009-03-31       Impact factor: 3.240

2.  The grass is not always greener: a multi-institutional pilot study of marijuana use and acute pain management following traumatic injury.

Authors:  Kristin Salottolo; Laura Peck; Allen Tanner Ii; Matthew M Carrick; Robert Madayag; Emmett McGuire; David Bar-Or
Journal:  Patient Saf Surg       Date:  2018-06-19

3.  Para-Aminobenzohydrazide Derivatives as Fatty Acid Amide Hydrolase Inhibitors: Design, Synthesis and Biological Evaluation.

Authors:  Anna Sedaghat; Elham Rezaee; Omid Hosseini; Sayyed Abbas Tabatabai
Journal:  Iran J Pharm Res       Date:  2020       Impact factor: 1.696

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.